MNPR · Monopar Therapeutics
$105.90
-5.22 (-4.70%)
At close · Jul 20
Market Cap
$709.43M
Shares
6.70M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2025-12-19 | Arthur Klausner | Board Member | 5,121 | 2025-12-18 | MLPFS |
| 2025-07-14 | Robinson Chandler | Officer, Director | 16,800 | 2025-07-14 | Merrill Lynch Pierce Fenner & Smith Inc. |
| 2025-07-14 | Tsuchimoto Kim R | Director | 8,904 | 2025-07-14 | Merrill Lynch Pierce Fenner & Smith Inc. |
| 2025-07-14 | STARR CHRISTOPHER M | Director | 16,800 | 2025-07-14 | Merrill Lynch Pierce Fenner & Smith Inc. |
| 2025-04-02 | Tactic Pharma LLC | 10% Stockholder | 33,334 | 2025-04-02 | Merrill Lynch, Pierce, Fenner & Smith, Inc. |
Showing 1–5 of 5 filings